WO2003020723A1 - [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE - Google Patents

[1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE Download PDF

Info

Publication number
WO2003020723A1
WO2003020723A1 PCT/JP2002/008666 JP0208666W WO03020723A1 WO 2003020723 A1 WO2003020723 A1 WO 2003020723A1 JP 0208666 W JP0208666 W JP 0208666W WO 03020723 A1 WO03020723 A1 WO 03020723A1
Authority
WO
WIPO (PCT)
Prior art keywords
triazolo
pyrimidine derivative
adenosine
receptor
derivative
Prior art date
Application number
PCT/JP2002/008666
Other languages
French (fr)
Japanese (ja)
Inventor
Hitoshi Arai
Daisuke Machii
Koji Hagihara
Michio Ichimura
Junichi Enokizono
Shizuo Shiozaki
Junichi Shimada
Koji Suzuki
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to JP2003524993A priority Critical patent/JPWO2003020723A1/en
Publication of WO2003020723A1 publication Critical patent/WO2003020723A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A [1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the formula (I): (I) wherein Y represents hydrogen or (un)substituted lower alkyl; Z represents oxygen or sulfur; and X represents (II) or (III) or a pharmacologically acceptable salt of the derivative. They have an antagonistic activity against an adenosine A2A receptor and are useful for treatments for and/or prevention of various diseases attributable to the hyperenergia of an adenosine A2A receptor, e.g., parkinsonism.
PCT/JP2002/008666 2001-08-30 2002-08-28 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE WO2003020723A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003524993A JPWO2003020723A1 (en) 2001-08-30 2002-08-28 [1,2,4] triazolo [1,5-a] pyrimidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-262095 2001-08-30
JP2001262095 2001-08-30

Publications (1)

Publication Number Publication Date
WO2003020723A1 true WO2003020723A1 (en) 2003-03-13

Family

ID=19089037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008666 WO2003020723A1 (en) 2001-08-30 2002-08-28 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE

Country Status (2)

Country Link
JP (1) JPWO2003020723A1 (en)
WO (1) WO2003020723A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (en) * 2002-05-23 2003-12-04 Amgen Inc. Calcium receptor modulating arylalkylamines
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
JP2012520854A (en) * 2009-03-20 2012-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Oxidized derivatives of triazolylpurine useful as ligands for adenosine A2A receptors and their use as drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0499775A (en) * 1990-08-20 1992-03-31 Dai Ichi Seiyaku Co Ltd 2-position substituted triazolopyrimidines
WO1999043678A1 (en) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0499775A (en) * 1990-08-20 1992-03-31 Dai Ichi Seiyaku Co Ltd 2-position substituted triazolopyrimidines
WO1999043678A1 (en) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (en) * 2002-05-23 2003-12-04 Amgen Inc. Calcium receptor modulating arylalkylamines
AU2003233671B8 (en) * 2002-05-23 2003-12-12 Amgen Inc. Calcium receptor modulating arylalkylamines
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7196102B2 (en) 2002-05-23 2007-03-27 Amgen Inc. Calcium receptor modulating agents
AU2003233671B2 (en) * 2002-05-23 2007-08-16 Amgen Inc. Calcium receptor modulating arylalkylamines
JP2010150268A (en) * 2002-05-23 2010-07-08 Amgen Calcium receptor modulating agent
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
JP2012520854A (en) * 2009-03-20 2012-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Oxidized derivatives of triazolylpurine useful as ligands for adenosine A2A receptors and their use as drugs

Also Published As

Publication number Publication date
JPWO2003020723A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
EP1505068A4 (en) PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
EP1700856A4 (en) Thiazole derivative
PT1159279E (en) 4-OXO-4,7-DIHYDROTIENE-2,3-B | PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
HK1064096A1 (en) Purine derivatives as a2b adenosine receptor antagonists.
NO20055510L (en) 2-alkynyl and 2-alkenylpyrazolo [4,3-E] -1,2,4-triazolo [1,5-C] pyrimidine-adenosine A2A receptor antagonists
CY1105553T1 (en) SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE FOR NEURODEGENERAL DISORDERS
WO2003035639A1 (en) Pyrimidine compound and medicinal composition thereof
WO2005049616A8 (en) 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
BG102478A (en) N-([1,2,4]triazolazinyl)benzenesulphonamide and pyridinesulphanamide compunds and their application as herbicides
DZ3359A1 (en) PYRROLO [2,3-d] PYRIMIDINE DERIVATIVES USEFUL AS IMMUNOSUPPRESSANT AGENTS
WO2004087677A3 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
MY126736A (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
TR200402342T4 (en) Derivatives of 2-Pyridinyl-6,7,8,9-Tetrahydropyrimido [1,2-A] pyrimidin-4-one and 7-pyrindinyl-1,3-dihydoimidazo [1,2-a] pyrimidin-5 (1H) one
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
TWI349674B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof
WO2005103052A8 (en) Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
WO2003068776A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
WO2004106339A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
WO2003008365A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
MXPA03003923A (en) N-([1,2,4]triazoloazinyl) thiophenesulfonamide compounds as herbicides.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003524993

Country of ref document: JP

122 Ep: pct application non-entry in european phase